Executive interview – Paion at EKF 2019

Published on 6 December 2019

In this interview, Dr James Phillips, CEO of Paion, provides an overview of the company and its focus on anaesthesia products. He explains what differentiates remimazolam from other anaesthetics, how the established clinical data are perceived by key opinion leaders, and what key milestones investors should watch out for in the next 12–24 months. He also discusses how remimazolam is being commercialised in key markets and why the company decided to self-commercialise the drug in the EU.

Share this with friends and colleagues